Aldose reductase: A multi-disease target

Current Enzyme Inhibition

Volumn 10, Issue 1, 2014, Pages 2-12

  Sangshetti, Jaiprakash N ^a   Chouthe, Rashmi S ^a   Sakle, Nikhil S ^a   Gonjari, Indrajeet ^b   Shinde, Devanand B ^c  

^a Y B CHAVAN COLLEGE OF PHARMACY   (India)

^b Govt College of Pharmacy   (India)

^c DR BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY   (India)

Author keywords

Aldose reductase inhibitors; Diabetic neuropathy; Inflammatory pathologies; Polyol pathway

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ALRESTATIN; ASCORBIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOKINE; FIDARESTAT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MINALRESTAT; PONALRESTAT; PROSTAGLANDIN E; PROTEIN KINASE C; RANIRESTAT; SORBINIL; TOLRESTAT; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ZENARESTAT; ZOPOLRESTAT;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DOWN REGULATION; GLOMERULAR DYSFUNCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; KIDNEY FAILURE; LIPID PEROXIDATION; NEUROPATHIC PAIN; NONHUMAN; OVARY DISEASE; PROTEIN PHOSPHORYLATION; REPERFUSION INJURY;

EID: 84900829645     PISSN: 15734080     EISSN: 18756662     Source Type: Journal    
DOI: 10.2174/15734080113096660007     Document Type: Article

References (105)

1. Nishimura-Yabe, C. Aldose reductase in the polyol pathway: a potential target for the therapeutic intervention of diabetic complications. Nihon Yakurigaku Zasshi., 1998, 111, 137-145.
2. Kinoshita, J.H.; Nishimura, C. The involvement of aldose reductase in diabetic complications. Diabetes Metab. Rev., 1988, 4, 323-337.
3. Matsuura, K.; Deyashiki, Y.; Bunai, Y.; Ohya, I.; Hara, A. Aldose reductase is a major reductase for isocaproaldehyde, a product of side-chain cleavage of cholesterol, in human and animal adrenal glands. Arch. Biochem. Biophys., 1996, 328, 265-271.
4. Kern, T.S.; Engerman, R.L. Immunohistochemical distribution of aldose reductase. Histochem. J., 1982, 14, 507-515.
5. Svanberg, B.; Ling, C.; Svensson, P.A.; Johnson, M.; Carlsson, B.; Billig, H. Isolation of differentially expressed aldose reductase in ovaries after estrogen withdrawal from hypophysectomized dieth-ylstilbestrol treated rats: increased expression during apoptosis. Mol. Cell Endocrinol., 2000, 164, 183-190.
6. Ludvigson, M.A.; Sorenson, R.L. Immunohistochemical localization of aldose reductase. I. Enzyme purification and antibody preparation-localization in peripheral nerve, artery, and testis. Diabetes, 1980, 29, 438-449.
7. Burg, M.B. Molecular basis of osmotic regulation. Am. J. Physiol., 1995, 268, 983-996.
8. Wermuth, B.; Monder, C. Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity. Eur. J. Biochem., 1983, 131, 423-426.
9. Rittner, H.L.; Hafner, V.; Klimiuk, P.A.; Szweda, L.I.; Goronzy, J.J.; Weyand, C.M. Aldose reductase functions as a detoxification system for lipid peroxidation products in vasculitis. J. Clin. Invest., 1999, 103, 1007-1013.
10. Cameron, N.E.; Cotter, M.A.; Hohman, T.C. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabe-tologia, 1996, 39, 172-182.
11. Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P.J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J., 2002, 16, 243-245.
12. Son, N.H.; Ananthakrishnan, R.; Yu, S.; Khan, R.S.; Jiang, H.; Ji, R.; Akashi, H.; Li, Q.; O'Shea, K.; Homma, S.; Goldberg, I.J.; Ramasamy, R. Cardiomyocyte aldose reductase causes heart failure and impairs recovery from ischemia. PLoS One, 2012, 7, e46549.
13. Ramana, K.V.; Srivastava, S.K. Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int. J. Biochem. Cell Biol., 2010, 42, 17-20.
14. Srivastava, S.K.; Yadav, U.C.; Reddy, A.B.; Saxena, A.; Tammali, R.; Shoeb, M.; Ansari, N.H.; Bhatnagar, A.; Petrash, M.J.; Srivas-tava, S.; Ramana, K.V. Aldose reductase inhibition suppresses oxi-dative stress-induced inflammatory disorders. Chem. Biol. Interact., 2011, 191, 330-338.
15. Regenold, W.T.; Kling, M.A.; Hauser, P. Elevated sorbitol concentration in the cerebrospinal fluid of patients with mood disorders. Psychoneuroendocrinology, 2000, 25, 593-606.
16. Hasuike, Y.; Nakanishi, T.; Otaki, Y.; Nanami, M.; Tanimoto, T.; Taniguchi, N.; Takamitsu, Y. Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reduc-tase in erythrocytes. Am. J. Kidney Dis., 2002, 40, 464-471.
17. Meyer, W.R.; Doyle, M.B.; Grifo, J.A.; Lipetz, K.J.; Oates, P.J.; DeCherney, A.H.; Diamond, M.P. Aldose reductase inhibition prevents galactose-induced ovarian dysfunction in the Sprague-Dawley rat. Am. J. Obstet. Gynecol., 1992, 167, 1837-1843.
18. Lee, K.W.; Ko, B.C.; Jiang, Z.; Cao, D.; Chung, S. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anticancer Drugs, 2001, 12, 129-132.
19. Saraswat, M.; Mrudula, T.; Kumar, P.U.; Suneetha, A.; Rao Rao, T.S.; Srinivasulu, M.; Reddy, B. Over-expression of aldose reduc-tase in human cancer tissues. Med. Sci. Monit., 2006, 12, 525-529.
20. Carper, D.A.; Wistow, G.; Nishimura, C.; Graham, C.; Watanabe, K.; Fujii, Y.; Hayashi, H.; Hayaishi, O. A superfamily of NADPH-dependent reductases in eukaryotes and prokaryotes. Exp. Eye Res., 1989, 49, 377-388.
21. Wilson, D.K.; Bohren, K.M.; Gabbay, K.H.; Quiocho, F.A. An unlikely sugar substrate site in the 1.65 A structure of the human aldose reductase holoenzyme implicated in diabetic complications. Science, 1992, 257, 81-84.
22. Rondeau, J.M.; Tete-Favier, F.; Podjarny, A.; Reymann, J.M.; Barth, P.; Biellmann, J.F.; Moras, D. Novel NADPH-binding domain revealed by the crystal structure of aldose reductase. Nature, 1992, 355, 469-472.
23. Wilson, D.K.; Tarle, I.; Petrash, J.M.; Quiocho, F.A. Refined 1.8 A structure of human aldose reductase complexed with the potent inhibitor zopolrestat. Proc. Natl. Acad. Sci. USA, 1993, 90, 9847-9851.
24. Kumar, H.; Shah, A.; Sobhia, M.E. Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors. J. Mol. Model., 2012, 18, 1791-1799.
25. Robison, W.G. Jr.; Tillis, T.N.; Laver, N.; Kinoshita, J.H. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp. Eye Res., 1990, 50, 355-366.
26. Ziegler, D. Treatment of diabetic neuropathy and neuropathic pain: how far have we come? Diabetes Care, 2008, 31, 255-261.
27. Tripathi, B.K.; Srivastava, A.K. Diabetes mellitus: complications and therapeutics. Med. Sci. Monit., 2006, 12, 130-147.
28. Greene, D.A.; Latimmer, S.A. Action of sorbinil in diabetic peripheral nerve. Relationship of polyol (sorbitol) pathway inhibition to a myo-inositol-mediated defect in sodium-potassium ATPase activity. Diabetes, 1984, 33, 712-716.
29. Hodgkin, A.L.; Keynes, R.D. Active transport of cations in giant axons from Sepia and Loligo. J. Physiol., 1955, 128, 28-60.
30. Stevens, M.J.; Dananberg, J.; Feldman, E.L.; Lattimer, S.A.; Ka-mijo, M.; Thomas, T.P.; Shindo, H.; Sima, A.A.; Greene, D.A. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J. Clin. Invest., 1994, 94, 853-859.
31. Kiernan, M.C. Emergence of a predictive clinical biomarker for diabetic neuropathy. Diabetes, 2012, 61, 1346-1347.
32. Vincent, A.M.; Russell, J.W.; Low, P.; Feldman, E.L. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev., 2004, 25, 612-628.
33. Obrosova, I.G.; Kador, P.F. Aldose reductase/polyol inhibitors for diabetic retinopathy. Curr. Pharm. Biotechnol., 2011, 12, 373-385.
34. Akagi, Y.; Kador, P.F.; Kuwabara, T.; Kinoshita, J.H. Aldose re-ductase localization in human retinal mural cells. Invest. Opthal-mol. Visual Sci., 1983, 24, 1516.
35. Lorenzi M. The polyol pathway as a mechanism for diabetic reti-nopathy: attractive, elusive and resilient. Exp. Diabetes Res., 2007, 2007, 61038.
36. Dagher, Z.; Park, Y.S.; Asnaghi, V.; Hoehn, T.; Gerhardinger, C.; Lorenzi, M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes, 2004, 53, 2404-2411.
37. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. Pharmacol. Rev., 1998, 50, 21-33.
38. Kador, P.F.; Akagi, Y.; Terubayashi, H.; Wyman, M.; Kinoshita, J.H. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch. Ophthal-mol., 1988, 106, 1099-1102.
39. Ramana, K.V.; Friedrich, B.; Srivastava, S.; Bhatnagar, A.; Srivas-tava, S.K. Activation of nuclear factor-kappaB by hyperglycemia in vascular smooth muscle cells is regulated by aldose reductase. Diabetes, 2004, 53, 2910-2920.
40. Harada, C.; Okumura, A.; Namekata, K.; Nakamura, K.; Mitamura, Y.; Ohguro, H.; Harada, T. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res. Clin. Pract., 2006, 74, 249-256.
41. Drel, V.R.; Pacher, P.; Ali, T.K.; Shin, J.; Julius, U.; El-Remessy, A.B.; Obrosova, I.G. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis. Int. J. Mol. Med., 2008, 21, 667-676.
42. Cooper, M.E. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia, 2001, 44, 1957-1972.
43. Dunlop, M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int., 2000, 58, 3-12.
44. Chang, W.P.; Dimitriadis, E.; Allen, T.; Dunlop, M.E.; Cooper, M.; Larkins, R.G. The effect of aldose reductase inhibitors on glomeru-lar prostaglandin production and urinary albumin excretion in experimental diabetes mellitus. Diabetologia, 1991, 34, 225-231.
45. Kassab, J.P.; Guillot, R.; Andre, J.; Claperon, N.; Bellon, G.; Feldmann, G.; Peyroux, J.; Sternberg, M. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies. Biochem. Pharmacol., 1994, 48, 1003-1008.
46. Passariello, N.; Sepe, J.; Marrazzo, G.; De Cicco, A.; Peluso, A.; Pisano, M.C.; Sgambato, S.; Tesauro, P.; D'Onofrio, F. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropa-thy. Diabetes Care, 1993, 16, 789-795.
47. Iso, K.; Tada, H.; Kuboki, K.; Inokuchi, T. Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J. Diabetes Complicat., 2001, 15, 241-244.
48. Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P.J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J., 2002, 16, 243-245.
49. Miller, S.I.; Ernst, R.K.; Bader, M.W. LPS, TLR4 and infectious disease diversity. Nat. Rev. Microb., 2005, 3, 36-46.
50. Yang, R.B.; Mark, M.R.; Gray, A.; Huang, A.; Xie, M.H.; Zhang, M.; Goddard, A.; Wood, W.I.; Gurney, A.L.; Godowski, P.J. Tolllike receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature, 1998, 395, 284-288.
51. Ramana, K.V.; Fadl, A.A.; Tammali, R.; Reddy, A.B.; Chopra, A.K.; Srivastava, S.K. Aldose reductase mediates the lipopolysac-charide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J. Biol. Chem., 2006, 281, 33019-33029.
52. Ramana, K.V.; Reddy, A.B.; Tammali, R.; Srivastava, S.K. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages. Free Radic. Biol. Med., 2007, 42, 1290-1302.
53. Yadav, U.C.S.; Srivastava, S.K.; Ramana, K.V. Aldose reductase inhibition prevents endotoxin-induced uveitis in rats. Invest. Ophth. Vis. Sci., 2007, 48, 4634-4642.
54. Pandey, S.; Srivastava, S.K.; Ramana, K.V. A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Exp. Opin. Investig. Drugs, 2012, 21, 329-339.
55. Yadav, U.C.S.; Ramana, K.V.; Srivastava, S.K. Aldose reductase inhibition suppresses airway inflammation. Chemico-Biological Interactions, 2011, 191, 339-345.
56. Abdillahi, M.; Ananthakrishnan, R.; Vedantham, S.; Shang, L.; Zhu, Z.; Rosario, R.; Zirpoli, H.; Bohren, K.M.; Gabbay, K.H.; Ramasamy, R. Aldose reductase modulates cardiac glycogen syn-thase kinase-3β phosphorylation during ischemia-reperfusion. Am. J. Physio. Heart Circ. Physiol., 2012, 303, 297-308.
57. Obrosova, I.G.; Maksimchyk, Y.; Pacher, P.; Agardh, E.; Smith, M.L.; El-Remessy, A.B.; Agardh, C.D. Evaluation of the aldose re-ductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. Int. J. Mol. Med., 2010, 26, 135-142.
58. Hwang, Y.C.; Kaneko, M.; Bakr, S.; Liao, H.; Lu, Y.; Lewis, E.R.; Yan, S.; Ii, S.; Itakura, M.; Rui, L.; Skopicki, H.; Homma, S.; Schmidt, A.M.; Oates, P.J.; Szabolcs, M.; Ramasamy, R. Central role for aldose reductase pathway in myocardial ischemic injury. FASEB J., 2004, 18, 1192-1199.
59. Chung, S.S.; Chung, S.K. Aldose reductase in diabetic microvascu-lar complications. Curr. Drug Targets, 2005, 6, 475-486.
60. Iwata, T.; Sato, S.; Jimenez, J.; McGowan, M.; Moroni, M.; Dey, A.; Ibaraki, N.; Reddy, V.N.; Carper, D. Osmotic response element is required for the induction of aldose reductase by tumor necrosis factor-alpha. J. Biol. Chem., 1999, 274, 7993-8001.
61. Ko, B.C.; Ruepp, B.; Bohren, K.M.; Gabbay, K.H.; Chung, S.S. Identification and characterization of multiple osmotic response sequences in the human aldose reductase gene. J. Biol. Chem., 1997, 272, 16431-16437.
62. Hwang, Y.C.; Sato, S.; Tsai, J.Y.; Yan, S.; Bakr, S.; Zhang, H.; Oates, P.J.; Ramasamy, R. Aldose reductase activation is a key component of myocardial response to ischemia. FASEB J., 2002, 16, 243-245.
63. Ramasamy, R.; Liu, P.J.; Oates, S.S. Attenuation of ischemia induced increases in sodium and calcium by the aldose reductase inhibitor Zopolrestat. Cardiovasc. Res, 1999, 42, 130-139.
64. Ross, R. The pathogenesis of atherosclerosis- A perspective for the 1990s. Nature, 1993, 362, 801-809.
65. Ramana, K.V.; Chandra, D.; Srivastava, S.; Bhatnagar, A.; Aggar-wal, B.B.; Srivastava, S.K. Aldose reductase mediates mitogenic signaling in vascular smooth muscle cells. J. Biol. Chem., 2002, 277, 32063-32070.
66. Jiang, T.; Che, C.; Lin, Y.; Li, L.; Zhang, N. Aldose reductase regulates TGF-β1-induced production of fibronectin and type IV collagen in cultured rat mesangial cells. Nephrology, 2006, 11, 105-112.
67. Hasuike, Y.; Moriguchi, R.; Hata, R.; Miyagawa, K.; Kuragano, T.; Aizawa, M.; Yamamoto, S.; Yanase, K.; Izumi, M.; Tanimoto, T.; Nakanishi, T. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis. Am. J. Nephrol., 2007, 27, 622-629.
68. Ramasamy, R.; Yan, S.F.; Schmidt, A.M. Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids, 2012, 42, 1151-1161.
69. Liu, G.; Hale, G.E.; Hughes, C. Galactose metabolism and ovarian toxicity. Reprod. Toxicol., 2000, 14, 377-384.
70. Berry, G.T. The role of polyols in the pathophysiology of hyperga-lactosemia. Eur. J. Pediatr., 1995, 154, S53-S64.
71. Alexiou, P.; Pegklidou, K.; Chatzopoulou, M.; Nicolaou, I.; De-mopoulos, V.J. Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr. Med. Chem., 2009, 16, 734-752.
72. Cao, D.; Tat F.S.; Chung, S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem., 1998, 273, 11429-11435.
73. Ax, W.; Soldan, M.; Koch, L.; Maser, E. Development of daunoru-bicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol., 2000, 59, 293-300.
74. Lee, E.K.; Tegenold, W.T.; Shapiro, P. Inhibition of aldose reduc-tase enhances HeLa cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases. Anti-Cancer Drug, 2002, 13, 859-868.
75. Gupta, R.A.; Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase -2. Nat. Rev. Cancer, 2001, 1, 11-21.
76. Tammali, R.; Ramana, K.V.; Singhal, S.S.; Awasthi, S.; Srivastava, K. Aldose reductase regulates growth factor-induced cyclooxy-genase- 2 expression and prostaglandin E2 production in human colon cancer cells. Cancer Res., 2006, 66, 9705-9713.
77. Kopf, D.; Goretzki, P.; Lehnert, H. Clinical management of malignant adrenal tumors. J. Cancer Res. Clin. Oncol., 2001, 127, 143-155.
78. Lefrancois-Martinez, A.M.; Bertherat, J.; Val, P.; Tournaire, C.; Gallo-Payet, N.; Hyndman, D.; Sveyssiere, G.; Bertagna, H.; Jean, C.; Martinez, A. Decreased expression of cyclic adenosine mono-phospate- regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors. J. Clin. En-docr. Metab., 2004, 89, 3010-3019.
79. Rosenberg, D.; Groussin, L.; Jullian, E.; Perlemoine, K.; Medjane, S.; Louvel, A.; Bertagna, X.; Bertherat, J. Transcription factor 3',5'-cyclic adenosine 5'-monophosphate-responsive elementbind-ing protein (CREB) is decreased during human adrenal cortex tu-morigenesis and fetal development. J. Clin. Endocrinol. Metab., 2003, 88, 3958-3965.
80. Kuhajda, F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition, 2000, 16, 202-208.
81. Cao, D.; Tat, F.S.; Chung, S. Identification and characterization of a novel human aldose reductase-like gene. J. Biol. Chem., 1998, 273, 11429-11435.
82. Sarges, R. US Pat. 1978, 4130714.
83. Dvornik, D.; Simard-Duquesne, N.; Krami, M.; Sestanj, K.; Gab-bay, K.H.; Kinoshita, J.H.; Varma, S.D.; Merola, L.O. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science, 1973, 182, 1146-1148.
84. Mylari, B.L.; Larson, E.R.; Beyer, T.A.; Zembrowski, W.J.; Ald- inger, C.E.; Dee, M.F.; Siegel, T.W.; Singleton, D.H. Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners. J. Med. Chem., 1991, 34, 108-122.
85. Bruno, G.; Constantino, L.; Curinga, C.; Maccari, R.; Monforte, F.; Nicolo, F.; Ottana, R.; Vigorita, G.M. Synthesis and aldose reduc-tase inhibitory activity of 5-arylidene-2,4-thiazolidinediones. Bioorg. Med. Chem., 2002, 10, 1077-1084.
86. Costantino, L.; Rastelli, G.; Gamberoni, M.C.; Barlocco, D. Pharmacological approaches to the treatment of diabetic complications. Exp. Opin. Ther. Pat., 2000, 10, 1245-1262.
87. Asano, T.; Saito, Y.; Kawakami, M.; Yamada, N.; Fidarestat Clinical Pharmacology Study Group. Fidarestat (SNK-860), a potent al-dose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. J. Diabetes. Complicat., 2002, 16, 133-138.
88. Rakowitz, D.; Maccari, R.; Ottana, R.; Vigorita, M.G. In vitro aldose reductase inhibitory activity of 5-benzyl-2,4-thiazolidinediones. Bioorg. Med. Chem., 2006, 14, 567-574.
89. Graham, A.; Brown, L.; Hedge, P.J.; Gammack, A.J.; Quiocho, F.A. Structure of the human aldose reductase gene. J. Biol. Chem., 1991, 266, 6872-6877.
90. Fagius, J.; Jameson, S.J. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysi-ological study. Neurol. Neurosurg. Psychiatr., 1981, 44, 991-1001.
91. Kamon, N.; Mabuchi, A.; Takeda, R.; Terashima, H. Effects of aldose reductase inhibitor (ONO-2235) on human erythrocyte sor-bitol concentrations in 75 g oral glucose tolerance tests. Horm. Me-tab. Res., 1991, 23, 226-229.
92. Stribling, D.; Mirrlees, D.J.; Harrison, H.E.; Earl, D.C. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism, 1985, 34, 336-344.
93. Ishii, H.; Tada, H.; Isogai, S. An aldose reductase inhibitor prevents glucose-induced increase in transforming growth factor-beta and protein kinase C activity in cultured mesangial cells. Diabetologia, 1998, 41, 362-364.
94. Negoro, T.; Murata, M.; Ueda, S.; Fujitani, B.; Ono, Y.; Kuromiya, A.; Komiya, M.; Suzuki, K.; Matsumoto, J. Novel, highly potent aldose reductase inhibitors: (R)-(-)-2-(4-Bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine- 4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone (AS-3201) and its congeners. J. Med. Chem., 1998, 41, 4118-4129.
95. Inoue, J.; Cui, Y.; Sakai, O.; Nakamura, Y.; Kogiso, H.; Kador, P. Synthesis and aldose reductase inhibitory activities of novel N-nitromethylsulfonanilide derivatives. Bioorg. Med. Chem., 2000, 8, 2167-2173.
96. Mylari, B.L.; Armento, S.J.; Beebe, D.A.; Conn, E.L.; Coutcher, J.B.; Dina, M.S.; O'Gorman, M.T.; Linhares, M.C.; Martin, W.H.; Oates, P.J.; Tess, D.A.; Withbroe, G.J.; Zembrowski, W.J. A novel series of non-carboxylic acid, non- hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congeners. J. Med. Chem., 2005, 48, 6326-6339.
97. Nicolaou, I.; Zika, C.; Demopoulos, V.J. 1-(3,5-difluoro-4- hy-droxyphenyl)-1H-pyrrol-3-yl) phenylmethanone as a bioisostere of a carboxylic acid aldose reductase inhibitor. J. Med. Chem., 2004, 47, 2706-2709.
98. Alexiou, P.; Nicolaou, I.; Stefek, M.; Kristl, A.; Demopoulos, V.J. Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl) ben-zenesulfonamides as aldose reductase inhibitors. Bioorg. Med. Chem., 2008, 16, 3926-3932.
99. Stefek, M.; Snirc, V.; Djoubissie, P.O.; Majekova, M.; Demopou-los, V.J.; Rackova, L.; Bezakova, Z.; Karasu, C.; Carbone, V.; El-Kabbani, O. Carboxymethylated pyridoindole antioxidants as al-dose reductase inhibitors: Synthesis, activity, partitioning, and molecular modeling. Bioorg. Med. Chem., 2008, 16, 4908-4920.
100. Ko, K.; Won, Y. Quantitative structure and aldose reductase inhibitory activity relationship of 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3-pyrrolidine-1,2-,3,5-tetrone derivatives. Bioorg. Med. Chem., 2005, 13, 1445-1452.
101. Maccari, R.; Ottana, R.; Curinga, C.; Vigorita, M.G.; Rakowitz, D.; Steindl, T.; Langer, T. Structure-activity relationships and molecular modelling of 5-arylidene-2,4-thiazolidinediones active as aldose reductase inhibitors. Bioorg. Med. Chem., 2005, 13, 2809-2823.
102. Sambasivara, S.G.; Soni, K.L.; Gupta, K.A.; Hanumantharao, P.; Kaskhedikar, S.G. Quantitative structure-activity analysis of 5-arylidene-2,4-thiazolidinediones as aldose reductase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 512-521.
103. Crabbe, M.J.; Goode, D. Aldose reductase: a window to the treatment of diabetic complications? Prog. Retin. Eye Res., 1998, 17, 313-383.
104. Nakai, N.; Fujii, Y.; Kobashi, K.; Nomura, K. Aldose reductase inhibitors: flavonoids, alkaloids, acetophenones, benzophenones, and spirohydantoins of chroman. Arch. Biochem. Biophys., 1985, 239, 491-496.
105. Saraswat, M.; Muthenna, P.; Suryanarayana, P.; Petrash, J.M.; Bhanuprakash, R.G.B. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac. J. Clin. Nutr., 2008, 17, 558-565.